ondansetron + droperidol

Ondansetron + droperidol is a fixed-dose combination of two antiemetic drugs used primarily for the prevention and treatment of postoperative nausea and vomiting (PONV). Ondansetron is a selective serotonin 5-hydroxytryptamine type-3 (5-HT3) receptor antagonist, while droperidol is a butyrophenone dopamine D2 receptor antagonist. The combination leverages the distinct mechanisms of action of each agent to provide enhanced antiemetic efficacy compared to monotherapy with either drug alone. Clinical studies have demonstrated that this combination reduces the incidence of PONV more effectively than either agent alone, with an additive effect on efficacy. Both agents can prolong the QT interval, but their effects are additive rather than synergistic at clinically relevant doses[1][2][5][6][7].